Top Tropical & Travel Medicine Research Papers

Overall: This national surveillance report offers directly applicable US epidemiologic information and supports existing mpox vaccination efforts, but its incomplete observational analysis and lack of absolute effects or safety data limit causal certainty and practice-changing impact.

Overall: This randomized trial found increased self-reported Japanese encephalitis vaccine uptake but no improvement in its primary decision-quality outcome, with limited relevance to routine US primary care and no demonstrated patient health benefit.

Overall: This small, single-arm open-label phase 2b study suggests olorofim may help patients with severe disseminated coccidioidomycosis who have few options, but absence of a control group and limited patient-centered hard outcomes constrain certainty and broad practice impact.

Overall: A rigorous, large-scale model-based burden analysis with patient-important endpoints, but it does not evaluate a clinical intervention, limiting direct net-benefit assessment and near-term practice change in primary care.

Overall: A small descriptive outbreak investigation showing Legionella contamination in hotel water systems and associated travel-related cases; it supports awareness and reporting but provides limited comparative evidence or quantified patient benefit from specific interventions.

Overall: Malaria in Children at 9 US Hospitals: 2016-2023 identifies delayed diagnosis as a concern using clinically important outcomes, but its retrospective design, lack of quantified intervention benefit, rarity in US primary care, and confirmation of established practice substantially limit its impact.

Overall: This randomized trial provides credible short-term evidence that both regimens remain highly effective and tolerable in Ethiopia, but it was not comparative, has limited US applicability, and is unlikely by itself to change practice.

Overall: The study supports transplant-program screening and prophylaxis using clinically meaningful outcomes, but its observational evidence, rare condition, and specialty setting sharply limit its relevance to routine US primary care.

Overall: This moderately sized randomized trial demonstrates high short-term efficacy and acceptable safety, but it offers limited comparative clinical advantage and little capacity to alter routine US practice.

Overall: This reasonably rigorous phase 2 trial establishes immunologic noninferiority and similar short-term safety, but its surrogate endpoint, investigational status, and narrow relevance to US primary care substantially limit its overall importance.